Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Frequently asked questions
What sector does Sandoz Group AG (D8Y0) operate in?
Sandoz Group AG belongs to the Other sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Sandoz Group AG (D8Y0) current stock price?
As of the latest data, Sandoz Group AG stock price is €88.00, with a previous close of €88.00.
What is Sandoz Group AG (D8Y0) current market capitalization?
Sandoz Group AG market cap is approximately 38.08 billion.
What is Sandoz Group AG (D8Y0) Earnings Per Share (EPS)?
The trailing EPS is €1.26.
What is Sandoz Group AG (D8Y0) Price-to-Earnings (P/E) ratio?
Sandoz Group AG current P/E ratio is 69.84.
Does Sandoz Group AG (D8Y0) pay dividends?
Yes. Sandoz Group AG pays annual dividends with an annualized yield of 1.12% and an estimated annual payout of €0.91 per share.
When is the next ex-dividend date for Sandoz Group AG (D8Y0)?
The next ex-dividend date is scheduled for April 14, 2027.
What is Sandoz Group AG (D8Y0) beta (volatility) score?
Sandoz Group AG has a beta of 0.491, indicating lower volatility than the overall market.
